Myovant and Pfizer Publish the Results of Relugolix Combination Regimen in P-III LIBERTY Studies in NEJM

 Myovant and Pfizer Publish the Results of Relugolix Combination Regimen in P-III LIBERTY Studies in NEJM

Myovant and Pfizer Publish the Results of Relugolix Combination Regimen in P-III LIBERTY Studies in NEJM

Shots:

  • The P-III LIBERTY 1 & 2 studies involve assessing of relugolix (40mg) + estradiol (1.0mg) & norethindrone acetate (0.5mg) vs PBO in women with uterine fibroids
  • The results showed response rates in menstrual blood loss (73.4% & 71.2%) vs (18.9% & 14.7%) @24wks; 84.3% reduction in menstrual blood loss from baseline; maintained bone mineral density; reduction of pain; improvement in anemia and was well tolerated respectively
  • Data from LIBERTY 1& 2 study, in addition to the 28-week long-term extension study, were included in the NDA) for relugolix combination tablet with anticipated PDUFA date as Jun 01, 2021

Click here ­to­ read full press release/ article | Ref: Pfizer | Image: Myovant

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post